Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma
Biochemical Pharmacology · 2024-07 · 225 · 116294
DOI: 10.1016/j.bcp.2024.116294 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024-07. Verfasst von Yuting Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan 030000, China; Department of Pathobiology and Immu…. Hauptthemen laut MEDLINE: Artemisinins, Carcinoma, Hepatocellular, Glucose Transporter Type 1, Glycolysis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Aerobic glycolysis is a hallmark of hepatocellular carcinoma (HCC). Dihydroartemisinin (DHA) exhibits antitumor activity towards liver cancer. Our previous studies have shown that DHA inhibits the Warburg effect in HCC cells. However, the mechanism still needs to be clarified. Our study aimed to elucidate the interaction between YAP1 and GLUT1-mediated aerobic glycolysis in HCC cells and focused on the underlying mechanisms of DHA inhibiting aerobic glycolysis in HCC cells. In this study, we confirmed that inhibition of YAP1 expression lowers GLUT1-mediated aerobic glycolysis in HCC cells and enhances the activity of CD8+T cells in the tumor niche. Then, we found that DHA was bound to cellular YAP1 in HCC cells. YAP1 knockdown inhibited GLUT1-mediated aerobic glycolysis, whereas YAP1 overexpression promoted GLUT1-mediated aerobic glycolysis in HCC cells. Notably, liver-specific Yap1 knockout by AAV8-TBG-Cre suppressed HIF-1α and GLUT1 expression in tumors but not para-tumors in DEN/TCPOBOP-induced HCC mice. Even more crucial is that YAP1 forms a positive feedback loop with GLUT1-mediated aerobic glycolysis, which is associated with HIF-1α in HCC cells. Finally, DHA reduced GLUT1-aerobic glycolysis in HCC cells through YAP1 and prevented the binding of YAP1 and HIF-1α. Collectively, our study revealed the mechanism of DHA inhibiting glycolysis in HCC cells from a perspective of a positive feedback loop involving YAP1 and GLUT1 mediated-aerobic glycolysis and provided a feasible therapeutic strategy for targeting enhanced aerobic glycolysis in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan 030000, China; Department of Pathobiology and Immunology, Hebei University of Chinese Medicine, Shijiazhuang, 050200, Ch…
- Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan 030000, China.
Zitieren
APA
Gao, Y., Gong, Y., Lu, J., Yang, Y., Zhang, Y., Xiong, Y., & Shi, X. (2024). Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma. Biochemical Pharmacology, 225, 116294. https://doi.org/10.1016/j.bcp.2024.116294
Vancouver
Gao Y, Gong Y, Lu J, Yang Y, Zhang Y, Xiong Y, et al. Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma. Biochemical Pharmacology. 2024;225:116294. doi:10.1016/j.bcp.2024.116294
BibTeX
@article{Gao2024,
author = {Gao, Yuting and Gong, Yi and Lu, Junlan and Yang, Yanguang and Zhang, Yuman and Xiong, Yajun and Shi, Xinli},
title = {Dihydroartemisinin breaks the positive feedback loop of YAP1 and GLUT1-mediated aerobic glycolysis to boost the CD8+ effector T cells in hepatocellular carcinoma},
journal = {Biochemical Pharmacology},
year = {2024},
volume = {225},
pages = {116294},
doi = {10.1016/j.bcp.2024.116294}
}
EUVIMED